Trial Profile
A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Emprumapimod (Primary)
- Indications Dilated cardiomyopathy
- Focus Registrational; Therapeutic Use
- Acronyms REALM-DCM
- Sponsors Array BioPharma; Pfizer
- 04 Feb 2024 This trial has been discontinued in Italy according to European Clinical Trials Database record.
- 19 Jan 2023 This trial has been discontinued in Spain according to European Clinical Trials Database record.
- 18 Aug 2022 This trial has been completed in Belgium (Date of the global end of the trial : 02-Aug-2022), according to European Clinical Trials Database record.